Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties
Authors (first, second and last of 9)
Collection
Preclinical Molecular Imaging and Cancer Theranostics
Molecular imaging is rapidly changing the diagnostic landscape for a variety of human diseases, especially cancers. With a growing understanding of the pathogenesis and development of human diseases, various targets or molecular events have been harnessed to develop molecular imaging tracers or theranostic agents, which further improve the management of diseases upon clinical translation. Although translating and promoting radiopharmaceuticals for clinical use is a long-term goal, we should embrace preclinical development and evaluation of radiopharmaceuticals, especially those that address unmet clinical challenges. In this collection, we welcome colleagues to contribute preclinical yet promising work on radiopharmaceuticals.
Editors
-
Weijun Wei
A physician-scientist majoring in nuclear medicine and molecular imaging at Renji Hospital, School of Medicine, Shanghai Jiao Tong University. As an active nuclear medicine physician and associate professor at the university hospital, he is dedicated to developing novel protein-based radiopharmaceuticals for imaging and treating cancers.
-
Dawei Jiang
Prof. at the Department of Nuclear Medicine, Wuhan Union Hospital, Huazhong University of Science and Technology (HUST), China. His research interests include the design and development of DNA and antibody-based tracers for medical imaging and disease treatment. He has authored >100 academic papers and was awarded "2019 Ones to Watch" and "Michael J. Welch Postdoctoral Award" by the Society of Nuclear Medicine and Molecular Imaging. He is currently the Editor-in-Chief of Am. J. Nucl. Med. Mol. Imaging and editorial board members of Journal of Nanobiotechnology and Molecular Pharmaceutics.
Articles (48 in this collection)
-
-
Homodimeric peptide radiotracer [68Ga]Ga-NOTA-(TMVP1)2 for VEGFR-3 imaging of cervical cancer patients
Authors (first, second and last of 18)
-
Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer
Authors (first, second and last of 9)
-
Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients
Authors (first, second and last of 7)
-
Preclinical evaluation of 68 Ga-labeled peptide CK2 for PET imaging of NRP-1 expression in vivo
Authors (first, second and last of 7)
-
Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [169Yb]Yb2O3 nanoseeds
Authors (first, second and last of 11)
-
A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging
Authors (first, second and last of 9)
-
Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer
Authors (first, second and last of 10)
-
Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive l-[methyl-11C] methionine cohort study with two PET scanners
Authors (first, second and last of 11)
-
[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models
Authors (first, second and last of 8)
-
-
In vitro and in vivo characterization of [64Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors
Authors (first, second and last of 6)
-
Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside
Authors (first, second and last of 10)
-
An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy
Authors (first, second and last of 7)
-
ImmunoPET imaging–based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model
Authors (first, second and last of 14)
-
Translational assessment of a DATA-functionalized FAP inhibitor with facile 68Ga-labeling at room temperature
Authors (first, second and last of 13)
-
-
Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42
Authors (first, second and last of 11)
-
Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma
Authors (first, second and last of 12)
-
In vivo evaluation of a novel 18F-labeled PET radioligand for translocator protein 18 kDa (TSPO) in monkey brain
Authors (first, second and last of 12)
-
Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma
Authors (first, second and last of 9)
-
Biodistribution and radiation dosimetry in cancer patients of the ascorbic acid analogue 6-Deoxy-6-[18F] fluoro-L-ascorbic acid PET imaging: first-in-human study
Authors (first, second and last of 8)
-
Preclinical evaluation of a novel EGFR&c-Met bispecific near infrared probe for visualization of esophageal cancer and metastatic lymph nodes
Authors (first, second and last of 8)
-
Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy
Authors (first, second and last of 9)
-
First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection
Authors (first, second and last of 16)
-
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression
Authors (first, second and last of 20)
-
Superfluous, controversial and luxury issues in nuclear medicine
Authors (first, second and last of 8)
-
Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients
Authors (first, second and last of 9)
-
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition
Authors (first, second and last of 14)
-
First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2
Authors (first, second and last of 17)
-
89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
Authors (first, second and last of 14)
-
Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates
Authors (first, second and last of 18)
-
-
[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial
Authors (first, second and last of 6)
-
Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake
Authors (first, second and last of 11)
-
Noninvasive evaluation of PD-L1 expression in non-small cell lung cancer by immunoPET imaging using an acylating agent–modified antibody fragment
Authors (first, second and last of 10)
-
Variabilities in global DNA methylation and β-sheet richness establish spectroscopic landscapes among subtypes of pancreatic cancer
Authors (first, second and last of 14)
-
An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer
Authors (first, second and last of 9)
-
Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
Authors (first, second and last of 16)
-
99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types
Authors (first, second and last of 11)
-
Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39)
Authors (first, second and last of 7)
-
Non-invasive molecular imaging for precision diagnosis of metastatic lymph nodes: opportunities from preclinical to clinical applications
Authors (first, second and last of 8)
-
Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer
Authors (first, second and last of 10)
-
Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
Authors (first, second and last of 12)
-
Chlorin e6-loaded goat milk-derived extracellular vesicles for Cerenkov luminescence-induced photodynamic therapy
Authors (first, second and last of 10)
-
New and effective EGFR-targeted fluorescence imaging technology for intraoperative rapid determination of lung cancer in freshly isolated tissue
Authors (first, second and last of 8)
-
High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers
Authors (first, second and last of 11)
-
First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours
Authors (first, second and last of 12)
